28 October 2021 | News
The first integrated digital PCR solution is ideal for oncology, cell and gene therapy development
Thermo Fisher Scientific has introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays.
Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. The device supports the pharmaceutical fraternity in innovating disease management, advancing significantly in generating consistent and accurate data.
QuantStudio Absolute Q Digital PCR System is a much-needed solution in biotech and research-academia space,” said Amit Chopra, managing director, India, and South Asia, Thermo Fisher Scientific. “The device overcomes the existing challenges of precision, operation, and turnaround time to provide an industry-best dPCR platform," added Amit.